Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

CARD14E138A signalling in keratinocytes induces TNF-dependent skin and systemic inflammation

dc.contributor.authorManils Pacheco, Joan
dc.contributor.authorWebb, Louise V.
dc.contributor.authorHowes, Ashleigh
dc.contributor.authorJanzen, Julia
dc.contributor.authorBoeing, Stefan
dc.contributor.authorBowcock, Anne M.
dc.contributor.authorLey, Steven C.
dc.date.accessioned2025-05-19T14:49:08Z
dc.date.available2025-05-19T14:49:08Z
dc.date.issued2020-06-29
dc.date.updated2025-05-19T14:49:09Z
dc.description.abstractTo investigate how the CARD14E138A psoriasis-associated mutation induces skin inflammation, a knock-in mouse strain was generated that allows tamoxifen-induced expression of the homologous Card14E138A mutation from the endogenous mouse Card14 locus. Heterozygous expression of CARD14E138A rapidly induced skin acanthosis, immune cell infiltration and expression of psoriasis-associated pro-inflammatory genes. Homozygous expression of CARD14E138A induced more extensive skin inflammation and a severe systemic disease involving infiltration of myeloid cells in multiple organs, temperature reduction, weight loss and organ failure. This severe phenotype resembled acute exacerbations of generalised pustular psoriasis (GPP), a rare form of psoriasis that can be caused by CARD14 mutations in patients. CARD14E138A-induced skin inflammation and systemic disease were independent of adaptive immune cells, ameliorated by blocking TNF and induced by CARD14E138A signalling only in keratinocytes. These results suggest that anti-inflammatory therapies specifically targeting keratinocytes, rather than systemic biologicals, might be effective for GPP treatment early in disease progression.
dc.format.extent32 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec723848
dc.identifier.issn2050-084X
dc.identifier.pmid32597759
dc.identifier.urihttps://hdl.handle.net/2445/221115
dc.language.isoeng
dc.publishereLife Sciences
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.7554/eLife.56720
dc.relation.ispartofeLife, 2020, vol. 9
dc.relation.urihttps://doi.org/10.7554/eLife.56720
dc.rightscc-by (c) Manils, Joan et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationPsoriasi
dc.subject.classificationPèptids
dc.subject.classificationDermatitis
dc.subject.classificationAnimals
dc.subject.otherPsoriasis
dc.subject.otherPeptides
dc.subject.otherDermatitis
dc.subject.otherAnimals
dc.titleCARD14E138A signalling in keratinocytes induces TNF-dependent skin and systemic inflammation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
250922.pdf
Mida:
8.19 MB
Format:
Adobe Portable Document Format